Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Foliglurax
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Other names | DT2331; PXT-002331; PXT-2331 |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C23H23N3O3S |
Molar mass | 421.52 g·mol−1 |
3D model (JSmol) | |
| |
|
Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4), which is under development by Prexton Therapeutics for the treatment of Parkinson's disease. It reached phase II clinical trials, but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distinguish itself from placebo to meet the study endpoints.